Guobang Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	5,919	5,867	5,327	5,704	4,493	4,199
Other Revenue	23.85	23.85	22.35	17.33	12.43	7.07
Revenue	5,943	5,891	5,349	5,721	4,505	4,206
Revenue Growth (YoY)	4.00%	10.12%	-6.49%	26.98%	7.11%	10.63%
Cost of Revenue	4,461	4,455	4,141	4,190	3,212	2,799
Gross Profit	1,482	1,435	1,209	1,531	1,294	1,407
Selling, General & Admin	341.51	345.57	365.25	339.93	297.29	241.05
Research & Development	208.2	215.05	190.51	197.54	155.27	137.19
Other Operating Expenses	34.98	25.81	30.96	31.9	23.67	24.54
Operating Expenses	590.78	598.5	579.55	581.08	478.27	402.36
Operating Income	890.91	836.84	629.3	949.97	815.55	1,005
Interest Expense	-22.7	-27.28	-22.58	-16.55	-28.72	-35.52
Interest & Investment Income	34.76	42.89	65	48.9	22.66	16.89
Currency Exchange Gain (Loss)	32.46	32.46	22.04	58.72	-14.48	-48.39
Other Non Operating Income (Expenses)	-10.15	-5.48	-7.41	-4.31	-2.13	-11.39
EBT Excluding Unusual Items	925.28	879.43	686.35	1,037	792.88	926.2
Gain (Loss) on Sale of Investments	11.56	14.4	10.34	4.56	6.26	0.03
Gain (Loss) on Sale of Assets	14.78	-9.11	0.72	-15.84	0.3	-1.52
Asset Writedown	36.82	-6.54	-5.8	-0.05	-9.31	-5.31
Other Unusual Items	9.78	9.78	6.04	10.24	16.65	24.03
Pretax Income	998.22	887.97	697.65	1,036	806.78	943.44
Income Tax Expense	128.39	107.39	87.67	115.02	100.55	133.15
Earnings From Continuing Operations	869.83	780.58	609.98	920.62	706.23	810.29
Minority Interest in Earnings	3.13	1.02	2.49	0.28	-0.2	-0.29
Net Income	872.95	781.6	612.46	920.9	706.03	810
Net Income to Common	872.95	781.6	612.46	920.9	706.03	810
Net Income Growth	24.30%	27.62%	-33.49%	30.43%	-12.84%	157.19%
Shares Outstanding (Basic)	556	558	557	558	512	474
Shares Outstanding (Diluted)	556	558	557	558	512	474
Shares Change (YoY)	-0.21%	0.27%	-0.24%	9.09%	8.01%	-0.28%
EPS (Basic)	1.57	1.40	1.10	1.65	1.38	1.71
EPS (Diluted)	1.57	1.40	1.10	1.65	1.38	1.71
EPS Growth	24.57%	27.27%	-33.33%	19.56%	-19.30%	159.09%
Free Cash Flow	597.08	287.29	-231.68	213.92	-624.23	246.27
Free Cash Flow Per Share	1.07	0.52	-0.42	0.38	-1.22	0.52
Dividend Per Share	0.606	0.606	0.302	0.600	0.700	-
Dividend Growth	100.92%	100.92%	-49.74%	-14.29%	-	-
Gross Margin	24.93%	24.37%	22.60%	26.76%	28.72%	33.45%
Operating Margin	14.99%	14.21%	11.76%	16.61%	18.10%	23.88%
Profit Margin	14.69%	13.27%	11.45%	16.10%	15.67%	19.26%
Free Cash Flow Margin	10.05%	4.88%	-4.33%	3.74%	-13.86%	5.85%
EBITDA	1,408	1,270	950.43	1,210	1,016	1,162
EBITDA Margin	23.69%	21.55%	17.77%	21.15%	22.56%	27.62%
D&A For EBITDA	516.6	432.83	321.14	260.21	200.9	157.11
EBIT	890.91	836.84	629.3	949.97	815.55	1,005
EBIT Margin	14.99%	14.21%	11.76%	16.61%	18.10%	23.88%
Effective Tax Rate	12.86%	12.09%	12.57%	11.11%	12.46%	14.11%
Revenue as Reported	5,943	5,891	5,349	5,721	4,505	4,206
Advertising Expenses	-	1.94	1.52	3.42	1.2	1.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.